KR100695599B1 - 백신 - Google Patents

백신 Download PDF

Info

Publication number
KR100695599B1
KR100695599B1 KR1020027002036A KR20027002036A KR100695599B1 KR 100695599 B1 KR100695599 B1 KR 100695599B1 KR 1020027002036 A KR1020027002036 A KR 1020027002036A KR 20027002036 A KR20027002036 A KR 20027002036A KR 100695599 B1 KR100695599 B1 KR 100695599B1
Authority
KR
South Korea
Prior art keywords
rotavirus
vaccine composition
nucleotide sequence
antacid
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020027002036A
Other languages
English (en)
Korean (ko)
Other versions
KR20020092344A (ko
Inventor
브리지떼 데시르에 알베르테 콜라우
프랑소와즈 데나무르
이사벨레 노트
아닉크 폴리스즈크작
조지스 써리
빈센트 반데벨데
Original Assignee
글락소스미스클라인 바이오로지칼즈 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9919468.0A external-priority patent/GB9919468D0/en
Priority claimed from GBGB9927336.9A external-priority patent/GB9927336D0/en
Application filed by 글락소스미스클라인 바이오로지칼즈 에스.에이. filed Critical 글락소스미스클라인 바이오로지칼즈 에스.에이.
Publication of KR20020092344A publication Critical patent/KR20020092344A/ko
Application granted granted Critical
Publication of KR100695599B1 publication Critical patent/KR100695599B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12351—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Birds (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020027002036A 1999-08-17 2000-08-15 백신 Expired - Lifetime KR100695599B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9919468.0A GB9919468D0 (en) 1999-08-17 1999-08-17 Vaccine
GB9919468.0 1999-08-17
GB9927336.9 1999-11-18
GBGB9927336.9A GB9927336D0 (en) 1999-11-18 1999-11-18 Vaccine

Publications (2)

Publication Number Publication Date
KR20020092344A KR20020092344A (ko) 2002-12-11
KR100695599B1 true KR100695599B1 (ko) 2007-03-14

Family

ID=26315853

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027002036A Expired - Lifetime KR100695599B1 (ko) 1999-08-17 2000-08-15 백신

Country Status (42)

Country Link
US (4) US7285280B1 (enExample)
EP (1) EP1212084B1 (enExample)
JP (3) JP2003507040A (enExample)
KR (1) KR100695599B1 (enExample)
CN (1) CN100379451C (enExample)
AP (1) AP1768A (enExample)
AR (1) AR029643A1 (enExample)
AT (1) ATE327765T1 (enExample)
AU (1) AU767885B2 (enExample)
BG (1) BG65314B1 (enExample)
BR (1) BRPI0013357B8 (enExample)
CA (1) CA2379196C (enExample)
CO (1) CO5580165A1 (enExample)
CY (2) CY1106103T1 (enExample)
CZ (1) CZ302173B6 (enExample)
DE (2) DE122006000026I1 (enExample)
DK (1) DK1212084T3 (enExample)
DZ (1) DZ3219A1 (enExample)
EA (1) EA005952B1 (enExample)
ES (1) ES2260046T3 (enExample)
FR (1) FR06C0018I2 (enExample)
HK (1) HK1046860B (enExample)
HU (2) HU228975B1 (enExample)
IL (3) IL147926A0 (enExample)
LU (1) LU91251I2 (enExample)
MA (1) MA25489A1 (enExample)
MX (1) MXPA02001648A (enExample)
MY (1) MY133158A (enExample)
NL (1) NL300233I2 (enExample)
NO (2) NO328112B1 (enExample)
NZ (1) NZ517131A (enExample)
OA (1) OA12312A (enExample)
PE (1) PE20010487A1 (enExample)
PL (1) PL205550B1 (enExample)
PT (1) PT1212084E (enExample)
SI (1) SI1212084T1 (enExample)
SK (1) SK287261B6 (enExample)
TR (1) TR200200420T2 (enExample)
TW (1) TWI283270B (enExample)
UA (1) UA77388C2 (enExample)
UY (1) UY26297A1 (enExample)
WO (1) WO2001012797A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287261B6 (sk) * 1999-08-17 2010-04-07 Smithkline Beecham Biologicals S.A. Oslabená ľudská rotavírusová populácia, spôsob jej výroby, vakcínový prostriedok s jej obsahom a jej použitie
US6592869B2 (en) * 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
GB0020089D0 (en) * 2000-08-15 2000-10-04 Smithkline Beecham Biolog Vaccine Composition
KR20030026654A (ko) * 2001-09-26 2003-04-03 주식회사 씨트리 인간 로타바이러스의 활성을 저해하는 항체의 생산용 항원및 그의 제조방법과 이용
GB0414787D0 (en) 2004-07-01 2004-08-04 Glaxosmithkline Biolog Sa Method
MXPA06002459A (es) * 2003-09-02 2006-06-20 Glaxosmithkline Biolog Sa Vacuna.
GB0503337D0 (en) * 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
JP5519934B2 (ja) * 2005-08-17 2014-06-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 異型交差防御を誘導するロタウイルスワクチン
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
KR101051986B1 (ko) * 2006-09-28 2011-07-26 중앙대학교 산학협력단 인간로타바이러스 및 이를 이용한 백신 조성물
US20090047255A1 (en) 2006-11-03 2009-02-19 Alphavax, Inc. Alphavirus and Alphavirus Replicon Particle Formulations and Methods
EP2236617A1 (en) 2009-03-31 2010-10-06 Leukocare Ag Methods of terminal sterilization of biofunctional compositions
CA3121471A1 (en) 2009-05-12 2010-11-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention New human rotavirus strains and vaccines
RU2553331C2 (ru) * 2009-07-13 2015-06-10 Бхарат Байотек Интернэшнл Лимитед Композиция, применимая в качестве ротавирусной вакцины, и способ ее получения
FR2960781B1 (fr) * 2010-06-07 2013-11-22 Sanofi Pasteur Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue
CN110227152A (zh) 2012-04-23 2019-09-13 巴拉特生物技术国际有限公司 轮状病毒疫苗组合物及其制备方法
EP2888355B1 (en) * 2012-08-27 2020-06-17 Murdoch Childrens Research Institute Modified human rotaviruses and uses therefor
HRP20211838T1 (hr) * 2015-05-21 2022-03-04 Xiamen University Krnji protein vp4 rotavirusa i njegova primjena
EP3359651A1 (en) 2015-10-05 2018-08-15 THE UNITED STATES OF AMERICA, represented by the S Human rota virus g9p[6]strain and use as a vaccine
WO2017081110A1 (en) * 2015-11-09 2017-05-18 Curevac Ag Rotavirus vaccines
JP2019502685A (ja) * 2015-12-18 2019-01-31 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 熱安定性ロタウイルスワクチン製剤およびその使用方法
MA44557B1 (fr) 2016-06-16 2021-11-30 Bharat Biotech Int Ltd Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
CN110856493B (zh) * 2018-08-20 2022-02-25 中国烟草总公司黑龙江省公司牡丹江烟草科学研究所 一种植物病毒弱毒疫苗组合物、弱毒疫苗保存方法及其应用
CA3224156A1 (en) 2021-06-28 2023-01-05 VST LLC dba Medgene Labs Sapovirus vaccines
WO2024242174A1 (ja) * 2023-05-24 2024-11-28 国立大学法人大阪大学 一回感染性ロタウイルスおよびその利用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341763A (en) 1981-03-10 1982-07-27 Smithkline-Rit Methods of vaccinating humans against rotavirus infection
US4571385A (en) 1983-06-27 1986-02-18 The United States Of America As Represented By The Department Of Health And Human Services Genetic reassortment of rotaviruses for production of vaccines and vaccine precursors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5927323B2 (ja) * 1976-10-12 1984-07-05 花王株式会社 歯みがき組成物
EP0152295B1 (en) * 1984-02-09 1991-03-20 Royal Children's Hospital Research Foundation Live attenuated human rotavirus vaccine and preparation thereof
US5626851A (en) * 1987-11-30 1997-05-06 The Wistar Institute Of Anatomy And Biology Rotavirus reassortant vaccine
WO1992008786A1 (en) * 1990-11-16 1992-05-29 James N. Gamble Institute Of Medical Research Human rotaviruses, vaccines and methods
US5471385A (en) * 1992-05-21 1995-11-28 Tsubakimoto Chain Co. Routeless guiding method for moving body
US5773009A (en) * 1994-04-15 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services Rotavirus strain G9P11
WO1996001651A1 (en) * 1994-07-11 1996-01-25 The Government Of The United States Of America, Represented By The Department Of Health And Human Services Attenuated human rotavirus vaccine
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
DE69738271T2 (de) * 1996-09-26 2008-08-28 Merck & Co., Inc. Rotavirus-impfstoff
US6403098B1 (en) * 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
SK287261B6 (sk) * 1999-08-17 2010-04-07 Smithkline Beecham Biologicals S.A. Oslabená ľudská rotavírusová populácia, spôsob jej výroby, vakcínový prostriedok s jej obsahom a jej použitie

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341763A (en) 1981-03-10 1982-07-27 Smithkline-Rit Methods of vaccinating humans against rotavirus infection
US4571385A (en) 1983-06-27 1986-02-18 The United States Of America As Represented By The Department Of Health And Human Services Genetic reassortment of rotaviruses for production of vaccines and vaccine precursors

Also Published As

Publication number Publication date
IL147926A (en) 2008-03-20
CN100379451C (zh) 2008-04-09
NZ517131A (en) 2003-07-25
SK287261B6 (sk) 2010-04-07
NO328112B1 (no) 2009-12-07
PE20010487A1 (es) 2001-06-23
NL300233I1 (nl) 2006-09-01
NO2010011I1 (no) 2010-06-07
CO5580165A1 (es) 2005-11-30
IL147926A0 (en) 2002-08-14
US7790179B2 (en) 2010-09-07
FR06C0018I1 (enExample) 2006-07-21
AU767885B2 (en) 2003-11-27
CA2379196A1 (en) 2001-02-22
OA12312A (en) 2006-05-12
UA77388C2 (uk) 2006-12-15
AP1768A (en) 2007-08-16
CY2006004I2 (el) 2009-11-04
FR06C0018I2 (fr) 2007-04-27
BG65314B1 (bg) 2008-01-31
BR0013357A (pt) 2002-04-30
CZ302173B6 (cs) 2010-11-24
WO2001012797A3 (en) 2001-08-02
DK1212084T3 (da) 2006-07-10
SI1212084T1 (sl) 2006-08-31
JP2003507040A (ja) 2003-02-25
HU228975B1 (en) 2013-07-29
US20090130145A1 (en) 2009-05-21
DZ3219A1 (fr) 2001-02-22
BRPI0013357B1 (pt) 2016-08-02
MA25489A1 (fr) 2002-07-01
HK1046860B (en) 2006-10-06
US7285280B1 (en) 2007-10-23
LU91251I2 (fr) 2006-08-14
EP1212084B1 (en) 2006-05-31
EP1212084A2 (en) 2002-06-12
KR20020092344A (ko) 2002-12-11
HUP0203335A1 (hu) 2003-02-28
EA200200142A1 (ru) 2002-08-29
PL354135A1 (en) 2003-12-29
AU6996100A (en) 2001-03-13
SK2432002A3 (en) 2002-09-10
AP2002002424A0 (en) 2002-03-31
JP2011045374A (ja) 2011-03-10
HUP0203335A3 (en) 2004-07-28
ATE327765T1 (de) 2006-06-15
MY133158A (en) 2007-10-31
IL188686A0 (en) 2008-04-13
LU91251I9 (enExample) 2018-12-31
WO2001012797A2 (en) 2001-02-22
CA2379196C (en) 2015-05-26
CZ2002522A3 (cs) 2002-05-15
JP5474720B2 (ja) 2014-04-16
US20080057082A1 (en) 2008-03-06
US7790180B2 (en) 2010-09-07
CY2006004I1 (el) 2009-11-04
JP2007319164A (ja) 2007-12-13
NO20020763L (no) 2002-04-16
AR029643A1 (es) 2003-07-10
DE60028390T2 (de) 2006-11-02
EA005952B1 (ru) 2005-08-25
MXPA02001648A (es) 2002-08-06
ES2260046T3 (es) 2006-11-01
BRPI0013357B8 (pt) 2021-05-25
TR200200420T2 (tr) 2002-05-21
NO20020763D0 (no) 2002-02-15
DE122006000026I1 (de) 2006-10-12
NL300233I2 (nl) 2006-10-02
TWI283270B (en) 2007-07-01
HUS1300072I1 (hu) 2019-11-28
CN1379683A (zh) 2002-11-13
NO2010011I2 (no) 2015-02-02
US20080063662A1 (en) 2008-03-13
HK1046860A1 (en) 2003-01-30
PL205550B1 (pl) 2010-04-30
BG106417A (en) 2003-04-30
UY26297A1 (es) 2001-03-16
CY1106103T1 (el) 2010-07-28
PT1212084E (pt) 2006-07-31
DE60028390D1 (de) 2006-07-06

Similar Documents

Publication Publication Date Title
JP5474720B2 (ja) ワクチン
JP5588586B2 (ja) ワクチン
DK2272532T3 (en) Rotavirus vaccine.
JP5519934B2 (ja) 異型交差防御を誘導するロタウイルスワクチン
EP1676586B1 (en) Method of separating rotavirus variants and live attenuated rotavirus vaccine
ZA200601771B (en) Vaccine

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20020216

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20050726

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20060803

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20070125

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20070308

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20070308

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20100122

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20110225

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20120228

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20130227

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20130227

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20140227

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20140227

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20150227

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20150227

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20151230

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20151230

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20161229

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20161229

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20171228

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20171228

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20181227

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20181227

Start annual number: 13

End annual number: 13

PC1801 Expiration of term

Termination date: 20210215

Termination category: Expiration of duration